Literature DB >> 26851599

Nonantimuscarinic treatment for overactive bladder: a systematic review.

Cedric K Olivera1, Kate Meriwether2, Sherif El-Nashar3, Cara L Grimes4, Chi Chiung Grace Chen5, Francisco Orejuela6, Danielle Antosh7, Jon Gleason8, Shunaha Kim-Fine9, Thomas Wheeler10, Brook McFadden11, Ethan M Balk12, Miles Murphy13.   

Abstract

The purpose of the study was to determine the efficacy and safety of nonantimuscarinic treatments for overactive bladder. Medline, Cochrane, and other databases (inception to April 2, 2014) were used. We included any study design in which there were 2 arms and an n > 100, if at least 1 of the arms was a nonantimuscarinic therapy or any comparative trial, regardless of number, if at least 2 arms were nonantimuscarinic therapies for overactive bladder. Eleven reviewers double-screened citations and extracted eligible studies for study: population, intervention, outcome, effects on outcome categories, and quality. The body of evidence for categories of interventions were summarized and assessed for strength. Ninety-nine comparative studies met inclusion criteria. Interventions effective to improve subjective overactive bladder symptoms include exercise with heat and steam generating sheets (1 study), diaphragmatic (1 study), deep abdominal (1 study), and pelvic floor muscle training exercises (2 studies). Pelvic floor exercises are more effective in subjective and objective outcomes with biofeedback or verbal feedback. Weight loss with diet and exercise, caffeine reduction, 25-50% reduction in fluid intake, and pelvic floor muscle exercises with verbal instruction and or biofeedback were all efficacious. Botulinum toxin A improves urge incontinence episodes, urgency, frequency, quality of life, nocturia, and urodynamic testing parameters. Acupuncture improves quality of life and urodynamic testing parameters. Extracorporeal magnetic stimulation improves urodynamic parameters. Mirabegron improves daily incontinence episodes, nocturia, number of daily voids, and urine volume per void, whereas solabegron improves daily incontinence episodes. Short-term posterior tibial nerve stimulation is more efficacious than pelvic floor muscle training exercises and behavioral therapy for improving: urgency, urinary incontinence episodes, daily voids, volume per void, and overall quality of life. Sacral neuromodulation is more efficacious than antimuscarinic treatment for subjective improvement of overactive bladder and quality of life. Transvaginal electrical stimulation demonstrates subjective improvement in overactive bladder symptoms and urodynamic parameters. Multiple therapies, including physical therapy, behavioral therapy, botulinum toxin A, acupuncture, magnetic stimulation, mirabegron, posterior tibial nerve stimulation, sacral neuromodulation, and transvaginal electrical stimulation, are efficacious in the treatment of overactive bladder.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  frequency; overactive bladder; treatment; urgency; urinary incontinence

Mesh:

Year:  2016        PMID: 26851599     DOI: 10.1016/j.ajog.2016.01.156

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  14 in total

1.  A comparative study of electroacupuncture at Zhongliao (BL33) and other acupoints for overactive bladder symptoms.

Authors:  Likun Yang; Yang Wang; Qian Mo; Zhishun Liu
Journal:  Front Med       Date:  2017-03-02       Impact factor: 4.592

2.  Uterine-preserving surgeries for the repair of pelvic organ prolapse: a systematic review with meta-analysis and clinical practice guidelines.

Authors:  Kate V Meriwether; Ethan M Balk; Danielle D Antosh; Cedric K Olivera; Shunaha Kim-Fine; Miles Murphy; Cara L Grimes; Ambereen Sleemi; Ruchira Singh; Alexis A Dieter; Catrina C Crisp; David D Rahn
Journal:  Int Urogynecol J       Date:  2019-02-11       Impact factor: 2.894

Review 3.  [Neuromodulation of lower urinary tract dysfunction].

Authors:  T M Kessler; S de Wachter
Journal:  Urologe A       Date:  2017-12       Impact factor: 0.639

Review 4.  Physical, Complementary, and Alternative Medicine in the Treatment of Pelvic Floor Disorders.

Authors:  Alex Arnouk; Elise De; Alexandra Rehfuss; Carin Cappadocia; Samantha Dickson; Fei Lian
Journal:  Curr Urol Rep       Date:  2017-06       Impact factor: 3.092

5.  Cholinergic Antagonists Combined with Electrical Stimulation or Bladder Training Treatments for Overactive Bladder in Female Adults: A Meta-Analysis of Randomized Controlled Trials.

Authors:  Yang Cao; Jianwei Lv; Chen Zhao; Jiayi Li; Jing Leng
Journal:  Clin Drug Investig       Date:  2016-10       Impact factor: 2.859

6.  Effectiveness of acupuncture for nocturia: A protocol for systematic review and meta-analysis.

Authors:  Yingjie Nie; Yushan Fan; Lilin Huang; Xiaojun Zhao; Ruikang Pang; Yijia Yang
Journal:  Medicine (Baltimore)       Date:  2021-05-21       Impact factor: 1.817

7.  Patient treatment preferences for symptomatic refractory urodynamic idiopathic detrusor overactivity.

Authors:  Christina L Fontaine; Ian Rudd; Mahreen Pakzad; Rizwan Hamid; Jeremy L Ockrim; Tamsin J Greenwell
Journal:  Urol Ann       Date:  2017 Jul-Sep

8.  Female Lower Urinary Tract Symptom Prevention and Treatment Strategies on Social Media: Mixed Correlation With Evidence.

Authors:  Claire S Burton; Gabriela Gonzalez; Kristina Vaculik; Carine Khalil; Yuliya Zektser; Corey Arnold; Christopher V Almario; Brennan M R Spiegel; Jennifer T Anger
Journal:  Urology       Date:  2020-07-13       Impact factor: 2.633

9.  Predictors of Nerve Stimulator Success in Patients With Overactive Bladder.

Authors:  Kristian D Stensland; Bennett Sluis; Jay Vance; Jared P Schober; Lara S MacLachlan; Arthur P Mourtzinos
Journal:  Int Neurourol J       Date:  2018-09-28       Impact factor: 2.835

10.  High Frequency Stimulation of the Pelvic Nerve Inhibits Urinary Voiding in Anesthetized Rats.

Authors:  Jonathan J Crook; Thelma A Lovick
Journal:  Front Physiol       Date:  2017-08-28       Impact factor: 4.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.